What type of study is this?

This is a Quantitative Study study.

September 12, 2025Neurology InternationalOpen Access

Cannabinoids in Chronic Pain: Clinical Outcomes, Adverse Effects and Legal Challenges

View Full Paper

Ask AI

Bookmark

Cannabinoids provide modest pain reduction, averaging 0.5–1.0 points on a 10-point scale, and can be condition-specific.
Discontinuation rates for high-dose CBD reach 12.9%, compared with 3.5% for placebo, indicating potential side effects.
Cannabinoids are primarily effective for neuropathic pain, while results for other conditions like fibromyalgia are inconsistent.
Regulatory challenges impede research and access, emphasizing the need for standardized formulations and harmonized guidelines.

No takes yet. Share an insight, caveat, or question.

Observational analysis shows modest analgesia in chronic pain conditions, highlighting safety and regulatory challenges.

Sič et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark